Curbstone Financial Management Corp’s VanEck Biotech ETF BBH Stock Holding History

Curbstone Financial Management Corp’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,450	Closed	-$438K	–	160
2015 Q4	$438K	Buy	3,450 +1,250	+57%	+$153K	0.15%	144
2015 Q3	$252K	Sell	2,200 -90	-4%	-$11.9K	0.18%	132
2015 Q2	$309K	Hold	2,290	–	–	0.21%	124
2015 Q1	$297K	Sell	2,290 -320	-12%	-$40.2K	0.2%	123
2014 Q4	$301K	Sell	2,610 -300	-10%	-$33.8K	0.23%	104
2014 Q3	$308K	Buy	2,910 +25	+0.9%	+$2.53K	0.24%	100
2014 Q2	$275K	Sell	2,885 -25	-0.9%	-$2.24K	0.21%	107
2014 Q1	$265K	Buy	+2,910	New	+$283K	0.22%	106

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LFM

Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Curbstone Financial Management Corp's BBH Position: Q1 2016 in Review

Curbstone Financial Management Corp sold out of VanEck Biotech ETF (BBH) in Q1 2016, closing a stake of 3,450 shares — an estimated $438K sold.

Curbstone Financial Management Corp first reported a position in BBH in Q1 2014 and held it in 8 quarters. The position peaked at $438K in Q4 2015. 71 funds tracked by Wall St. Rank hold BBH as of Q1 2016.

Curbstone Financial Management Corp reported no remaining VanEck Biotech ETF position as of Q1 2016 after selling out during the quarter.
Curbstone Financial Management Corp sold 3,450 VanEck Biotech ETF shares in Q1 2016, an estimated $438K.
Curbstone Financial Management Corp first reported a position in VanEck Biotech ETF in Q1 2014 and held it in 8 quarters.
Curbstone Financial Management Corp's VanEck Biotech ETF position peaked at $438K in Q4 2015.
71 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2016.

Based on Curbstone Financial Management Corp's 13F filing for Q1 2016, filed 5 Apr 2016.